The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Identifieur interne : 000243 ( Main/Exploration ); précédent : 000242; suivant : 000244The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Auteurs : Denny Kim [États-Unis] ; James S. Robertson [Royaume-Uni] ; Jean-Louis Excler [Corée du Sud] ; Richard C. Condit [États-Unis] ; Patricia E. Fast [États-Unis] ; Marc Gurwith [États-Unis] ; George Pavlakis [États-Unis] ; Thomas P. Monath [États-Unis] ; Jonathan Smith [États-Unis] ; David Wood [Royaume-Uni] ; Emily R. Smith [États-Unis] ; Robert T. Chen [États-Unis] ; Sonali Kochhar [États-Unis]Source :
- Vaccine [ 1873-2518 ] ; 2020.
Descripteurs français
- KwdFr :
- Appréciation des risques (méthodes), Appréciation des risques (normes), Humains (MeSH), Infections à coronavirus (génétique), Infections à coronavirus (prévention et contrôle), Opinion publique (MeSH), Vaccins antiviraux (effets indésirables), Vaccins antiviraux (génétique), Vaccins antiviraux (normes), Vaccins à ADN (effets indésirables), Vaccins à ADN (génétique), Vaccins à ADN (normes).
- MESH :
- effets indésirables : Vaccins antiviraux, Vaccins à ADN.
- génétique : Infections à coronavirus, Vaccins antiviraux, Vaccins à ADN.
- méthodes : Appréciation des risques.
- normes : Appréciation des risques, Vaccins antiviraux, Vaccins à ADN.
- prévention et contrôle : Infections à coronavirus.
- Humains, Opinion publique.
English descriptors
- KwdEn :
- COVID-19 Vaccines (MeSH), Coronavirus Infections (genetics), Coronavirus Infections (prevention & control), Humans (MeSH), Public Opinion (MeSH), Risk Assessment (methods), Risk Assessment (standards), Vaccines, DNA (adverse effects), Vaccines, DNA (genetics), Vaccines, DNA (standards), Viral Vaccines (adverse effects), Viral Vaccines (genetics), Viral Vaccines (standards).
- MESH :
- chemical , adverse effects : Vaccines, DNA, Viral Vaccines.
- chemical , genetics : Vaccines, DNA, Viral Vaccines.
- chemical , standards : Vaccines, DNA, Viral Vaccines.
- chemical : COVID-19 Vaccines.
- genetics : Coronavirus Infections.
- methods : Risk Assessment.
- prevention & control : Coronavirus Infections.
- standards : Risk Assessment.
- Humans, Public Opinion.
Abstract
Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of nucleic acid vaccines. This will facilitate the assessment by key stakeholders of potential safety issues and understanding of overall benefit-risk. The structured assessment provided by the template can also help improve communication and public acceptance of licensed nucleic acid vaccines.
DOI: 10.1016/j.vaccine.2020.06.017
PubMed: 32571717
PubMed Central: PMC7304391
Affiliations:
- Corée du Sud, Royaume-Uni, États-Unis
- Californie, Floride, Géorgie (États-Unis), Maryland, Massachusetts, New Jersey, Région capitale de Séoul, Washington (État)
- Seattle, Séoul
- Université de Washington
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.</title><author><name sortKey="Kim, Denny" sort="Kim, Denny" uniqKey="Kim D" first="Denny" last="Kim">Denny Kim</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Pharmaceuticals, Titusville, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Pharmaceuticals, Titusville, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Robertson, James S" sort="Robertson, James S" uniqKey="Robertson J" first="James S" last="Robertson">James S. Robertson</name><affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Independent Adviser</wicri:regionArea></affiliation></author><author><name sortKey="Excler, Jean Louis" sort="Excler, Jean Louis" uniqKey="Excler J" first="Jean-Louis" last="Excler">Jean-Louis Excler</name><affiliation wicri:level="3"><nlm:affiliation>International Vaccine Institute, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>International Vaccine Institute, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Condit, Richard C" sort="Condit, Richard C" uniqKey="Condit R" first="Richard C" last="Condit">Richard C. Condit</name><affiliation wicri:level="2"><nlm:affiliation>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Fast, Patricia E" sort="Fast, Patricia E" uniqKey="Fast P" first="Patricia E" last="Fast">Patricia E. Fast</name><affiliation wicri:level="2"><nlm:affiliation>International AIDS Vaccine Initiative, New York, NY 10004, USA; Stanford School of Medicine, Palo Alto, CA 94305, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>International AIDS Vaccine Initiative, New York, NY 10004, USA; Stanford School of Medicine, Palo Alto, CA 94305</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Gurwith, Marc" sort="Gurwith, Marc" uniqKey="Gurwith M" first="Marc" last="Gurwith">Marc Gurwith</name><affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Pavlakis, George" sort="Pavlakis, George" uniqKey="Pavlakis G" first="George" last="Pavlakis">George Pavlakis</name><affiliation wicri:level="2"><nlm:affiliation>National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Cancer Institute, National Institutes of Health, Frederick, MD 21702</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Monath, Thomas P" sort="Monath, Thomas P" uniqKey="Monath T" first="Thomas P" last="Monath">Thomas P. Monath</name><affiliation wicri:level="2"><nlm:affiliation>Crozet BioPharma LLC, Devens, MA 01434, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Crozet BioPharma LLC, Devens, MA 01434</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Smith, Jonathan" sort="Smith, Jonathan" uniqKey="Smith J" first="Jonathan" last="Smith">Jonathan Smith</name><affiliation wicri:level="2"><nlm:affiliation>VLP Therapeutics, Gaithersburg, MD 20878, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>VLP Therapeutics, Gaithersburg, MD 20878</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Wood, David" sort="Wood, David" uniqKey="Wood D" first="David" last="Wood">David Wood</name><affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Independent Adviser</wicri:regionArea></affiliation></author><author><name sortKey="Smith, Emily R" sort="Smith, Emily R" uniqKey="Smith E" first="Emily R" last="Smith">Emily R. Smith</name><affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Chen, Robert T" sort="Chen, Robert T" uniqKey="Chen R" first="Robert T" last="Chen">Robert T. Chen</name><affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Kochhar, Sonali" sort="Kochhar, Sonali" uniqKey="Kochhar S" first="Sonali" last="Kochhar">Sonali Kochhar</name><affiliation wicri:level="4"><nlm:affiliation>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA 98195, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA 98195</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32571717</idno><idno type="pmid">32571717</idno><idno type="doi">10.1016/j.vaccine.2020.06.017</idno><idno type="pmc">PMC7304391</idno><idno type="wicri:Area/Main/Corpus">000575</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000575</idno><idno type="wicri:Area/Main/Curation">000575</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000575</idno><idno type="wicri:Area/Main/Exploration">000575</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.</title><author><name sortKey="Kim, Denny" sort="Kim, Denny" uniqKey="Kim D" first="Denny" last="Kim">Denny Kim</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Pharmaceuticals, Titusville, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Pharmaceuticals, Titusville, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Robertson, James S" sort="Robertson, James S" uniqKey="Robertson J" first="James S" last="Robertson">James S. Robertson</name><affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Independent Adviser</wicri:regionArea></affiliation></author><author><name sortKey="Excler, Jean Louis" sort="Excler, Jean Louis" uniqKey="Excler J" first="Jean-Louis" last="Excler">Jean-Louis Excler</name><affiliation wicri:level="3"><nlm:affiliation>International Vaccine Institute, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>International Vaccine Institute, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Condit, Richard C" sort="Condit, Richard C" uniqKey="Condit R" first="Richard C" last="Condit">Richard C. Condit</name><affiliation wicri:level="2"><nlm:affiliation>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Fast, Patricia E" sort="Fast, Patricia E" uniqKey="Fast P" first="Patricia E" last="Fast">Patricia E. Fast</name><affiliation wicri:level="2"><nlm:affiliation>International AIDS Vaccine Initiative, New York, NY 10004, USA; Stanford School of Medicine, Palo Alto, CA 94305, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>International AIDS Vaccine Initiative, New York, NY 10004, USA; Stanford School of Medicine, Palo Alto, CA 94305</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Gurwith, Marc" sort="Gurwith, Marc" uniqKey="Gurwith M" first="Marc" last="Gurwith">Marc Gurwith</name><affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Pavlakis, George" sort="Pavlakis, George" uniqKey="Pavlakis G" first="George" last="Pavlakis">George Pavlakis</name><affiliation wicri:level="2"><nlm:affiliation>National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Cancer Institute, National Institutes of Health, Frederick, MD 21702</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Monath, Thomas P" sort="Monath, Thomas P" uniqKey="Monath T" first="Thomas P" last="Monath">Thomas P. Monath</name><affiliation wicri:level="2"><nlm:affiliation>Crozet BioPharma LLC, Devens, MA 01434, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Crozet BioPharma LLC, Devens, MA 01434</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Smith, Jonathan" sort="Smith, Jonathan" uniqKey="Smith J" first="Jonathan" last="Smith">Jonathan Smith</name><affiliation wicri:level="2"><nlm:affiliation>VLP Therapeutics, Gaithersburg, MD 20878, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>VLP Therapeutics, Gaithersburg, MD 20878</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Wood, David" sort="Wood, David" uniqKey="Wood D" first="David" last="Wood">David Wood</name><affiliation wicri:level="1"><nlm:affiliation>Independent Adviser, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Independent Adviser</wicri:regionArea></affiliation></author><author><name sortKey="Smith, Emily R" sort="Smith, Emily R" uniqKey="Smith E" first="Emily R" last="Smith">Emily R. Smith</name><affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Chen, Robert T" sort="Chen, Robert T" uniqKey="Chen R" first="Robert T" last="Chen">Robert T. Chen</name><affiliation wicri:level="2"><nlm:affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Kochhar, Sonali" sort="Kochhar, Sonali" uniqKey="Kochhar S" first="Sonali" last="Kochhar">Sonali Kochhar</name><affiliation wicri:level="4"><nlm:affiliation>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA 98195, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA 98195</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 Vaccines (MeSH)</term><term>Coronavirus Infections (genetics)</term><term>Coronavirus Infections (prevention & control)</term><term>Humans (MeSH)</term><term>Public Opinion (MeSH)</term><term>Risk Assessment (methods)</term><term>Risk Assessment (standards)</term><term>Vaccines, DNA (adverse effects)</term><term>Vaccines, DNA (genetics)</term><term>Vaccines, DNA (standards)</term><term>Viral Vaccines (adverse effects)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (standards)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Appréciation des risques (méthodes)</term><term>Appréciation des risques (normes)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (génétique)</term><term>Infections à coronavirus (prévention et contrôle)</term><term>Opinion publique (MeSH)</term><term>Vaccins antiviraux (effets indésirables)</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (normes)</term><term>Vaccins à ADN (effets indésirables)</term><term>Vaccins à ADN (génétique)</term><term>Vaccins à ADN (normes)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="standards" xml:lang="en"><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>COVID-19 Vaccines</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins à ADN</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Infections à coronavirus</term><term>Vaccins antiviraux</term><term>Vaccins à ADN</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Risk Assessment</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Appréciation des risques</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Appréciation des risques</term><term>Vaccins antiviraux</term><term>Vaccins à ADN</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Risk Assessment</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Public Opinion</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Opinion publique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of nucleic acid vaccines. This will facilitate the assessment by key stakeholders of potential safety issues and understanding of overall benefit-risk. The structured assessment provided by the template can also help improve communication and public acceptance of licensed nucleic acid vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32571717</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>34</Issue><PubDate><Year>2020</Year><Month>07</Month><Day>22</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.</ArticleTitle><Pagination><MedlinePgn>5556-5561</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(20)30789-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2020.06.017</ELocationID><Abstract><AbstractText>Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of nucleic acid vaccines. This will facilitate the assessment by key stakeholders of potential safety issues and understanding of overall benefit-risk. The structured assessment provided by the template can also help improve communication and public acceptance of licensed nucleic acid vaccines.</AbstractText><CopyrightInformation>Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Denny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceuticals, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>James S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Independent Adviser, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Excler</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>International Vaccine Institute, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Condit</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fast</LastName><ForeName>Patricia E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>International AIDS Vaccine Initiative, New York, NY 10004, USA; Stanford School of Medicine, Palo Alto, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurwith</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlakis</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monath</LastName><ForeName>Thomas P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Crozet BioPharma LLC, Devens, MA 01434, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VLP Therapeutics, Gaithersburg, MD 20878, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Independent Adviser, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Robert T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kochhar</LastName><ForeName>Sonali</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011639" MajorTopicYN="N">Public Opinion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Benefit-risk</Keyword><Keyword MajorTopicYN="Y">Brighton Collaboration</Keyword><Keyword MajorTopicYN="Y">CEPI</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">DNA</Keyword><Keyword MajorTopicYN="Y">Nucleic acid</Keyword><Keyword MajorTopicYN="Y">RNA</Keyword><Keyword MajorTopicYN="Y">Safety</Keyword><Keyword MajorTopicYN="Y">Template</Keyword><Keyword MajorTopicYN="Y">Vaccine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32571717</ArticleId><ArticleId IdType="pii">S0264-410X(20)30789-1</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2020.06.017</ArticleId><ArticleId IdType="pmc">PMC7304391</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccines (Basel). 2019 Apr 24;7(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">31022829</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Jan 1;33(1):62-72</Citation><ArticleIdList><ArticleId IdType="pubmed">25446819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Jan 1;33(1):73-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25305565</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2017 Sep;16(9):871-881</Citation><ArticleIdList><ArticleId IdType="pubmed">28701102</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2016 Dec 12;34(51):6597-6609</Citation><ArticleIdList><ArticleId IdType="pubmed">27395563</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2002 Dec 13;21(3-4):298-302</Citation><ArticleIdList><ArticleId IdType="pubmed">12450705</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2020 May;19(5):305-306</Citation><ArticleIdList><ArticleId IdType="pubmed">32273591</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2018 Apr;17(4):261-279</Citation><ArticleIdList><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine X. 2019 Jan 29;1:100009</Citation><ArticleIdList><ArticleId IdType="pubmed">31384731</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Apr 6;27(16):2282-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19056451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Californie</li><li>Floride</li><li>Géorgie (États-Unis)</li><li>Maryland</li><li>Massachusetts</li><li>New Jersey</li><li>Région capitale de Séoul</li><li>Washington (État)</li></region><settlement><li>Seattle</li><li>Séoul</li></settlement><orgName><li>Université de Washington</li></orgName></list><tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Kim, Denny" sort="Kim, Denny" uniqKey="Kim D" first="Denny" last="Kim">Denny Kim</name></region><name sortKey="Chen, Robert T" sort="Chen, Robert T" uniqKey="Chen R" first="Robert T" last="Chen">Robert T. Chen</name><name sortKey="Condit, Richard C" sort="Condit, Richard C" uniqKey="Condit R" first="Richard C" last="Condit">Richard C. Condit</name><name sortKey="Fast, Patricia E" sort="Fast, Patricia E" uniqKey="Fast P" first="Patricia E" last="Fast">Patricia E. Fast</name><name sortKey="Gurwith, Marc" sort="Gurwith, Marc" uniqKey="Gurwith M" first="Marc" last="Gurwith">Marc Gurwith</name><name sortKey="Kochhar, Sonali" sort="Kochhar, Sonali" uniqKey="Kochhar S" first="Sonali" last="Kochhar">Sonali Kochhar</name><name sortKey="Monath, Thomas P" sort="Monath, Thomas P" uniqKey="Monath T" first="Thomas P" last="Monath">Thomas P. Monath</name><name sortKey="Pavlakis, George" sort="Pavlakis, George" uniqKey="Pavlakis G" first="George" last="Pavlakis">George Pavlakis</name><name sortKey="Smith, Emily R" sort="Smith, Emily R" uniqKey="Smith E" first="Emily R" last="Smith">Emily R. Smith</name><name sortKey="Smith, Jonathan" sort="Smith, Jonathan" uniqKey="Smith J" first="Jonathan" last="Smith">Jonathan Smith</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Robertson, James S" sort="Robertson, James S" uniqKey="Robertson J" first="James S" last="Robertson">James S. Robertson</name></noRegion><name sortKey="Wood, David" sort="Wood, David" uniqKey="Wood D" first="David" last="Wood">David Wood</name></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Excler, Jean Louis" sort="Excler, Jean Louis" uniqKey="Excler J" first="Jean-Louis" last="Excler">Jean-Louis Excler</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000243 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000243 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32571717
|texte= The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32571717" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |